04-03-2019 02:51 PM CET - Health & Medicine

Acquired Immunodeficiency Syndrome (AIDS) Related Cancer Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Press release from: Pharma Proff

Acquired immunodeficiency syndrome (AIDS) related cancer include those types of cancer which occurs in patients suffering from AIDS.

Download the sample report @ www.pharmaproff.com/request-sample/1110

People with AIDS are reported to be highly suspected to the occurrence of lymphomas. According to the American Society of Clinical Oncology, Kaposi sarcoma is very common in patients with AIDS; whereas non-Hodgkin’s lymphoma is second most common in patients with AIDS.

Get the detailed analysis @ www.pharmaproff.com/report/aids-related-cancer-therapeuti...

Women with AIDS are at high risk for developing cervical intraepithelial neoplasia. The National Cancer Institute is in the process of developing chemotherapy and HAART; and EPOCH-rituximab, for the treatment of AIDS related lymphoma.

Make enquiry before purchase @ www.pharmaproff.com/enquiry/1110

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: www.pharmaproff.com

This release was published on openPR.
News-ID: 1686071 • Views: 93
More releasesMore releases

You can edit or delete your press release here: